Many angiopoietins, such as basic fibroblast growth factor(bFGF) and angiopoietin-2 (Ang-2), were found to correlate with VEGF and cEPCs in MMpatients; therefore, the addition of an anti-angiopoietin agent may improve the efficacyof anti-myeloma therapy (8). The gene discussed is VEGFA; the disease is plasma cell myeloma.